rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Asif Ali

Chief Financial Officer

Company insider

Files Form 4 as: Chief Financial Officer, Protagonist Therapeutics.

Every Form 4 they filed

In numbers

Trades disclosed
73
Buys
0
Sells
12
Bought
$0
Sold
$25.9M
Companies
1
Companies where not an officer
0
First trade
18 Apr 2022
Last trade
30 Sep 2026
Last filed
2 Oct 2026

Companies traded

Where they are an officer
PTGX Protagonist TherapeuticsOfficer · Biotechnology · last 30 Sep 20260 buys · 12 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
20Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
30 Sep 2026filed 2 Oct 2026PTGX Protagonist TherapeuticsBiotechnologySEC FORM 4 Code M$360K9,229 at $38.98filing
30 Sep 2026filed 2 Oct 2026PTGX Protagonist Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code M—5,312 at $0.00filing
30 Sep 2026filed 2 Oct 2026PTGX Protagonist TherapeuticsBiotechnologySEC FORM 4 Code M$666K28,438 at $23.42filing
30 Sep 2026filed 2 Oct 2026PTGX Protagonist TherapeuticsBiotechnologySEC FORM 4 Code M$300K15,650 at $19.19filing
30 Sep 2026filed 2 Oct 2026PTGX Protagonist TherapeuticsBiotechnologySEC FORM 4 Code M$65K5,312 at $12.17filing
30 Sep 2026filed 2 Oct 2026PTGX Protagonist TherapeuticsBiotechnologySEC FORM 4 Sold$1.8M12,595 at $141.77filing
30 Sep 2026filed 2 Oct 2026PTGX Protagonist TherapeuticsBiotechnologySEC FORM 4 Sold$6.5M46,034 at $141.78filing
30 Sep 2026filed 2 Oct 2026PTGX Protagonist Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code M—9,229 at $0.00filing
30 Sep 2026filed 2 Oct 2026PTGX Protagonist Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code M—28,438 at $0.00filing
30 Sep 2026filed 2 Oct 2026PTGX Protagonist Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code M—15,650 at $0.00filing
20 Apr 2026filed 21 Apr 2026PTGX Protagonist TherapeuticsBiotechnologySEC FORM 4 Sold$185K1,750 at $105.47filing
20 Apr 2026filed 21 Apr 2026PTGX Protagonist TherapeuticsBiotechnologySEC FORM 4 Sold$185K1,750 at $105.47filing
26 Mar 2026filed 27 Mar 2026PTGX Protagonist TherapeuticsBiotechnologySEC FORM 4 Code M$374K19,500 at $19.19filing
26 Mar 2026filed 27 Mar 2026PTGX Protagonist TherapeuticsBiotechnologySEC FORM 4 Code M$64K5,265 at $12.17filing
26 Mar 2026filed 27 Mar 2026PTGX Protagonist TherapeuticsBiotechnologySEC FORM 4 Sold$2.6M24,765 at $104.24filing
26 Mar 2026filed 27 Mar 2026PTGX Protagonist Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code M—19,500 at $0.00filing
26 Mar 2026filed 27 Mar 2026PTGX Protagonist Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code M—5,265 at $0.00filing
26 Mar 2026filed 27 Mar 2026PTGX Protagonist Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code M—19,500 at $0.00filing
26 Mar 2026filed 27 Mar 2026PTGX Protagonist Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code M—5,265 at $0.00filing
26 Mar 2026filed 27 Mar 2026PTGX Protagonist TherapeuticsBiotechnologySEC FORM 4 Code M$374K19,500 at $19.19filing

Sectors

Health Care12

Buys in green, sells in red, by the company’s sector.

Related people

Dinesh P.H. D. Patel VPresident and CEO · President and CEO at Protagonist Therapeutics, filing Form 4 there in the last year
William D. WaddillDirector · Director at Protagonist Therapeutics, filing Form 4 there in the last year
Bryan GiraudoCOO/CFO · Director at Protagonist Therapeutics, filing Form 4 there in the last year
Harold E. SelickDirector · Director at Protagonist Therapeutics, filing Form 4 there in the last year
Arturo MolinaChief Medical Officer · Chief Medical Officer at Protagonist Therapeutics, filing Form 4 there in the last year
Donald J. TrumpPresident · Also traded PTGX in the last 90 days